Home » Easai Launches H3 Biomedicine for R&D, Personalized Medicine
Easai Launches H3 Biomedicine for R&D, Personalized Medicine
Eisai Inc. launched a wholly owned research and development subsidiary in Cambridge called H3 Biomedicine Inc. that will focus on personalized cancer medicines based on cancer genetics and chemistry advances.
Mass High Tech
Mass High Tech
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May